| Dr Tariq Iqbal, MD, | |
|
850 Kempsville Rd, Ste 100f, Norfolk, VA 23502-3920 | |
| (757) 261-5910 | |
| (757) 275-9940 |
| Full Name | Dr Tariq Iqbal |
|---|---|
| Gender | Male |
| Speciality | Infectious Disease |
| Experience | 34 Years |
| Location | 850 Kempsville Rd, Norfolk, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194921783 | NPI | - | NPPES |
| VV1108A | Other | VA | MEDICARE PTAN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RI0200X | Internal Medicine - Infectious Disease | 0101243561 (Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sentara Princess Anne Hospital | Virginia beach, VA | Hospital |
| Sentara Leigh Hospital | Norfolk, VA | Hospital |
| Sentara Norfolk General Hospital | Norfolk, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sentara Medical Group | 8921903923 | 1058 |
News Archive
Access Pharmaceuticals, Inc., today announced it has initiated a Phase I/II dose-escalating study of its proprietary, anti-cancer drug, Thiarabine, a nucleoside analog for patients with hematologic malignancies (cancers of the blood). The primary objective of the study is to determine the maximum tolerated dose (MTD) in two different dosing schedules with various leukemias and lymphomas and recommended Phase II dose. The program is being led by Hagop Kantarjian, M.D., Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas.
University of Pittsburgh School of Medicine scientists have discovered the fastest way to identify potent, neutralizing human monoclonal antibodies against SARS-CoV-2, the virus that causes COVID-19.
Royal Philips Electronics and RXi Pharmaceuticals Corporation, a US-based biopharmaceutical company, today announced that they have entered into a joint research agreement to explore the benefits of combining proprietary technologies from both companies for the targeted delivery of experimental therapeutics based on RNA interference.
November is designated American Diabetes Month and while raising awareness this month about preventing diabetes is important, focusing on proper treatment is just as important for those living with the disease.
› Verified 6 days ago
| Entity Name | Sentara Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265485270 PECOS PAC ID: 8921903923 Enrollment ID: O20031203000466 |
News Archive
Access Pharmaceuticals, Inc., today announced it has initiated a Phase I/II dose-escalating study of its proprietary, anti-cancer drug, Thiarabine, a nucleoside analog for patients with hematologic malignancies (cancers of the blood). The primary objective of the study is to determine the maximum tolerated dose (MTD) in two different dosing schedules with various leukemias and lymphomas and recommended Phase II dose. The program is being led by Hagop Kantarjian, M.D., Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas.
University of Pittsburgh School of Medicine scientists have discovered the fastest way to identify potent, neutralizing human monoclonal antibodies against SARS-CoV-2, the virus that causes COVID-19.
Royal Philips Electronics and RXi Pharmaceuticals Corporation, a US-based biopharmaceutical company, today announced that they have entered into a joint research agreement to explore the benefits of combining proprietary technologies from both companies for the targeted delivery of experimental therapeutics based on RNA interference.
November is designated American Diabetes Month and while raising awareness this month about preventing diabetes is important, focusing on proper treatment is just as important for those living with the disease.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Tariq Iqbal, MD, 850 Kempsville Rd Ste 100f, Norfolk, VA 23502-3920 Ph: (757) 261-5910 | Dr Tariq Iqbal, MD, 850 Kempsville Rd, Ste 100f, Norfolk, VA 23502-3920 Ph: (757) 261-5910 |
News Archive
Access Pharmaceuticals, Inc., today announced it has initiated a Phase I/II dose-escalating study of its proprietary, anti-cancer drug, Thiarabine, a nucleoside analog for patients with hematologic malignancies (cancers of the blood). The primary objective of the study is to determine the maximum tolerated dose (MTD) in two different dosing schedules with various leukemias and lymphomas and recommended Phase II dose. The program is being led by Hagop Kantarjian, M.D., Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas.
University of Pittsburgh School of Medicine scientists have discovered the fastest way to identify potent, neutralizing human monoclonal antibodies against SARS-CoV-2, the virus that causes COVID-19.
Royal Philips Electronics and RXi Pharmaceuticals Corporation, a US-based biopharmaceutical company, today announced that they have entered into a joint research agreement to explore the benefits of combining proprietary technologies from both companies for the targeted delivery of experimental therapeutics based on RNA interference.
November is designated American Diabetes Month and while raising awareness this month about preventing diabetes is important, focusing on proper treatment is just as important for those living with the disease.
› Verified 6 days ago
Ranjana Neelanjana Mitra, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 830 Kempsville Rd Fl 1, Norfolk, VA 23502 Phone: 757-261-8070 | |
Arunava Paul, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 830 Kempsville Rd, Norfolk, VA 23502 Phone: 757-967-8622 Fax: 757-686-0541 | |
Abbas Asgher Ali, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 600 Gresham Dr, Ste B, Norfolk, VA 23507 Phone: 757-388-3198 Fax: 757-388-4242 | |
Peter B Laplace, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 426 E Freemason St, Norfolk, VA 23510 Phone: 757-623-6072 Fax: 757-623-9748 | |
Dr. Dace Auzins, M.D. Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 6316 Richmond Cres, Norfolk, VA 23508 Phone: 757-423-8560 | |
Dr. John S Carrick, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 850 Kempsville Rd, 1st Fl, Norfolk, VA 23502 Phone: 757-261-5283 Fax: 757-261-5849 | |
Dr. Rajden E Kutelia, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 600 Gresham Dr Fl 5, Norfolk, VA 23507 Phone: 757-388-3198 Fax: 757-388-4242 |